Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stryker Corp (NY:SYK)

395.28 +3.47 (+0.89%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Stryker Corp

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
A Glimpse Into The Expert Outlook On Stryker Through 14 Analysts
Via Benzinga
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts upgraded Stryker Corp (NYSE: SYK) after its Q4 report beat expectations, with strong sales and earnings growth projected for 2025. 
Via Benzinga
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
U.S. stock futures were mixed ahead of the crucial earnings from key U.S. technology companies and the Fed's expected pause on rate cuts. 
Via Benzinga
Topics Economy
Stryker Earnings Report: Q4 Overview
Via Benzinga
Stryker Earnings Review: Q4 Summary
Via Benzinga
Stryker Earnings Analysis: Q4 Recap
Via Benzinga
Stryker Q4 Earnings Assessment
Via Benzinga
Tesla, Starbucks And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Stryker Undercuts Breakout On Sales Deal, Despite Quarterly Beat
Stryker stock dipped late Tuesday after the medtech company beat forecasts, but announced its plan to divest the U.S. spinal business. 
Via Investor's Business Daily
Insights into Stryker Q4 Earnings
Via Benzinga
Earnings Summary: Stryker Q4
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
Via Benzinga
How Is The Market Feeling About Stryker?
Via Benzinga
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Stryker Stock In The Last 20 Years
Via Benzinga
How Is The Market Feeling About Stryker?
Via Benzinga
Here's How Much You Would Have Made Owning Stryker Stock In The Last 10 Years
Via Benzinga
Earnings Scheduled For January 28, 2025
Via Benzinga
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
These mid-cap stocks had impressive gains last week, including Inari Medical, Unifirst Corporation, and Walgreens. Are they in your portfolio? 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Stryker
Via Benzinga
Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position
Stryker acquires Inari Medical in a $4.9 billion deal, enhancing its vascular portfolio with innovative VTE treatments and a growing global reach. 
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Inari Medical Catapults 30% On Rumored Stryker Takeover
Inari is best-known for its series of catheter-like devices that remove blood clots. 
Via Investor's Business Daily
3 Stocks Helping to Bring AI to Healthcare
Many profitable companies are using AI to make healthcare more efficient; and these companies are rewarding investors with share price growth and dividends 
Via MarketBeat
Topics Artificial Intelligence
Top 10 Dividend Champions
Via Talk Markets
Topics Stocks / Equities
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth. 
Via The Motley Fool
PepsiCo To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.